We are live on ! Find out more
BHVN

Biohaven Pharmaceutical Holding Company Ltd.

Delisted

BHVN was delisted on the 3rd of October, 2022.

226 hedge funds and large institutions have $4.34B invested in Biohaven Pharmaceutical Holding Company Ltd. in 2020 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 77 increasing their positions, 63 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

347% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 15

325% more call options, than puts

Call options by funds: $160M | Put options by funds: $37.7M

122% more capital invested

Capital invested by funds: $1.95B → $4.34B (+$2.39B)

60% more funds holding in top 10

Funds holding in top 10: 1016 (+6)

29% more funds holding

Funds holding: 175226 (+51)

22% more repeat investments, than reductions

Existing positions increased: 77 | Existing positions reduced: 63

Holders
226
Holders Change
+51
Holders Change %
+29.14%
% of All Funds
4.63%
Holding in Top 10
16
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+60%
% of All Funds
0.33%
New
67
Increased
77
Reduced
63
Closed
15
Calls
$160M
Puts
$37.7M
Net Calls
+$122M
Net Calls Change
+$22M
Name Holding Trade Value Shares
Change
Change in
Stake
EAM
26
Eagle Asset Management
Florida
$44.7M -$5.16M -96,940 -13%
Deutsche Bank
27
Deutsche Bank
Germany
$44.6M +$2.36M +44,314 +8%
AIP
28
ARS Investment Partners
New York
$44.2M +$117K +2,206 +0.4%
CAM
29
Cormorant Asset Management
Massachusetts
$43.9M -$14.7M -275,551 -31%
Northern Trust
30
Northern Trust
Illinois
$42.9M +$3.29M +61,824 +12%
SC
31
Samlyn Capital
New York
$39.2M +$28.6M +536,530 New
Norges Bank
32
Norges Bank
Norway
$37.5M +$380K +7,135 +1%
CCI
33
Columbus Circle Investors
$36.7M +$26.7M +502,229 New
AC
34
Armistice Capital
New York
$36.6M -$29.6M -556,000 -53%
EA
35
Emerald Advisers
Pennsylvania
$36.2M -$4.52M -84,960 -15%
CTA
36
Carillon Tower Advisers
Florida
$34M -$3.04M -57,100 -11%
EP
37
Eversept Partners
New York
$32.8M +$18.2M +341,879 +321%
EMFAT
38
Emerald Mutual Fund Advisers Trust
Pennsylvania
$32.1M -$3.9M -73,251 -14%
Goldman Sachs
39
Goldman Sachs
New York
$31.1M +$816K +15,327 +4%
NM
40
NWI Management
New York
$29.2M
EAM
41
EULAV Asset Management
Florida
$28.6M +$1.12M +21,000 +6%
Charles Schwab
42
Charles Schwab
California
$23.1M +$1.57M +29,530 +10%
AAP
43
Ardsley Advisory Partners
Connecticut
$22.1M -$3.69M -69,350 -19%
N
44
Nuveen
North Carolina
$22M +$6.22M +116,876 +63%
Citadel Advisors
45
Citadel Advisors
Florida
$21.8M +$4.45M +83,694 +39%
ClearBridge Investments
46
ClearBridge Investments
New York
$20.4M +$14.9M +279,345 New
Handelsbanken Fonder
47
Handelsbanken Fonder
Sweden
$17.9M -$144K -2,700 -1%
HRCM
48
Hood River Capital Management
Florida
$16.5M +$12M +226,282 New
RPAM
49
Rhenman & Partners Asset Management
Sweden
$15.4M +$3.73M +70,000 +50%
VOYA Investment Management
50
VOYA Investment Management
Georgia
$15.2M -$4.64M -87,196 -30%

BHVN Hedge Fund Activity: Q2 2020 in Review

226 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Biohaven Pharmaceutical Holding Company Ltd. (BHVN) for Q2 2020, worth a combined $4.34B — up 122% from $1.95B a quarter earlier.

Buyers outnumbered sellers: 67 funds opened new BHVN positions and 15 closed out — a net gain of 52 holders — while 77 added to existing stakes and 63 trimmed.

The largest buyer was Tang Capital Management, opening a new position worth an estimated $52.2M. The largest seller was Wellington Management Group, cutting an estimated $55.1M.

  • 226 institutional investors held Biohaven Pharmaceutical Holding Company Ltd. (BHVN) as of Q2 2020, up from 175 in Q1 2020.
  • Funds reported $4.34B of Biohaven Pharmaceutical Holding Company Ltd. stock for Q2 2020, up 122% quarter-over-quarter.
  • 67 funds opened new Biohaven Pharmaceutical Holding Company Ltd. positions in Q2 2020 and 15 closed out, a net change of +52 holders.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. buyer in Q2 2020 was Tang Capital Management, an estimated $52.2M added.
  • The largest Biohaven Pharmaceutical Holding Company Ltd. seller in Q2 2020 was Wellington Management Group, an estimated $55.1M sold.

Based on aggregated 13F filings for Q2 2020.